Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.20.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Statement [Abstract]    
Product Revenue $ 363,515 $ 612,123
Product Cost of Sales (172,871) (245,937)
Gross Income 190,644 366,186
Research and Development Expenses 2,483,057
Administrative Expenses 1,157,732 982,953
Sales and Marketing Expenses 14,463 149,841
Regulatory and Compliance Expenses 72,091 88,391
Litigation Settlement Expenses 75,000
Amortization of Non-Current Assets 8,874 10,003
Loss from Operations (3,545,573) (940,002)
Other (Income) Expenses    
Impairment of Non-Current Assets 2,952
Foreign Currency Transaction Loss 4,659
Loss on Investments 36,714 3,718
Interest and Dividend Income (46,703) (31,421)
Total Other Income (7,037) (23,044)
Loss Before Income Taxes (3,538,536) (916,958)
Income Tax Benefit
Net Loss (3,538,536) (916,958)
Other Comprehensive Income (Loss)    
Net Unrealized Gain (Loss) on Marketable Securities (240,937) 29,343
Total Other Comprehensive Income (Loss) (240,937) 29,343
Comprehensive Loss $ (3,779,473) $ (887,615)
Basic and Diluted loss per common share $ (1.59) $ (1.70)
Weighted average basic and diluted common shares outstanding 2,226,847 540,628